The Food and Drug Administration (FDA) has approved Wegovy ® (semaglutide) tablets, the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of obesity.
The KINECT-DCP trial evaluated the efficacy and safety of valbenazine in patients with dyskinesia due to cerebral palsy who experience choreiform movements.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results